Skyrizi (risankizumab-rzaa) is a prescription injection that’s used to treat certain autoimmune disorders, such as plaque psoriasis and Crohn’s disease. Skyrizi comes in a few different forms ...

One of these medicines, Skyrizi, was approved for the treatment of moderate or severe plaque psoriasis in 2019. Clinical research shows that this injectable medicine may work better than some of ...

NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 meeting.

New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL ...

People with psoriatic arthritis (PsA) often take medicines to help manage their condition and improve their symptoms. Some of these medicines work directly on the body’s immune system and help ...

Citing results published by the British Journal of Dermatology in a head-to-head study, AbbVie’s Skyrizi was deemed more effective when compared to Amgen’s Otezla among adult patients with moderate ...

Credit: Thinkstock. Risankizumab is an interlekin-23 inhibitor; apremilast is a phosphodiesterase 4 inhibitor. Risankizumab (Skyrizi ®) was found to significantly improve clinical outcomes in ...

as compared with every 12 weeks with a drug like risankizumab [Skyrizi]," she said. "Patients really love that because they can kind of live their lives as though they don't have psoriasis." ...

Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin and improved the severity of disease in a phase 3 test, setting up the company to seek approval from Chinese ...

AbbVie stock popped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, ...

"While psoriasis/IBD/RA are all immune-mediated ... He pointed to newer induction studies, for example, with risankizumab (Skyrizi) and guselkumab (Tremfya), focused on giving newly diagnosed ...